Tecentriq Plus Chemotherapy Wins Approval for Stage III dMMR Colon Cancer After Halving Recurrence or Death Risk
The FDA approved Tecentriq plus chemotherapy after surgery for stage III dMMR colon cancer after a trial halved the risk of recurrence or death.
Medical Daily ·